1. Search Result
Search Result
Results for "

PKA

" in MedChemExpress (MCE) Product Catalog:

204

Inhibitors & Agonists

5

Screening Libraries

3

Fluorescent Dye

17

Biochemical Assay Reagents

33

Peptides

20

Natural
Products

4

Recombinant Proteins

6

Isotope-Labeled Compounds

6

Antibodies

14

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-115732

    PKA Inflammation/Immunology
    PKA-IN-1 is a potent and selective cyclic AMP-dependent protein kinase (PKA) catalytic subunit (cAK) inhibitor with an IC50 of 0.03 μM .
    PKA-IN-1
  • HY-P1290A
    PKA Inhibitor Fragment (6-22) amide TFA
    2 Publications Verification

    PKI-(6-22)-amide TFA

    PKA Neurological Disease
    PKA Inhibitor Fragment (6-22) amide TFA is an inhibitor of cAMP-dependent protein kinase A (PKA), with a Ki of 2.8 nM. PKA Inhibitor Fragment (6-22) amide TFA can significantly reverse antinociceptive tolerance in mice .
    PKA Inhibitor Fragment (6-22) amide TFA
  • HY-P0228A

    PKA Metabolic Disease
    PKA RII peptide TFA is a PKA substrate that, after being phosphorylated at the serine residue, can be used for the detection of calcineurin activity .
    PKA RII peptide TFA
  • HY-P1290

    PKI-(6-22)-amide

    PKA Neurological Disease
    PKA Inhibitor Fragment (6-22) amide is an inhibitor of cAMP-dependent protein kinase A (PKA), with a Ki of 2.8 nM. PKA Inhibitor Fragment (6-22) amide can significantly reverse low-level morphine antinociceptive tolerance in mice .
    PKA Inhibitor Fragment (6-22) amide
  • HY-P10098

    PKA Cancer
    PKA Substrate is a potent and selective substrate peptide of PKA that can be used to detect PKA activity .
    PKA Substrate
  • HY-P0228

    PKA Neurological Disease
    PKA RII peptide is a PKA substrate that, after being phosphorylated at the serine residue, can be used for the detection of calcineurin activity .
    PKA RII peptide
  • HY-148868

    Akt PKA CDK Others
    Akt1&PKA-IN-1 is a potent dual Akt/PKA inhibitor with IC50 values of 0.03 , 0.11 μM, and 9.8 μM for PKAa, Akt, and CDK2, respectively. Akt1&PKA-IN-1 is selective for cyclin-dependent kinase 2 (CDK2) .
    Akt1&PKA-IN-1
  • HY-148868A

    Akt CDK Cancer
    Akt1&PKA-IN-2 ((R)-29) is an inhibitor of PKB/AKT with cyclin-dependent kinase 2 (CDK2) selectivity. Akt1&PKA-IN-2 inhibits AKT1, PKAa and CDK2 a with IC50 values of 0.007 µM, 0.01 µM and 0.69 µM, respectively .
    Akt1&PKA-IN-2
  • HY-P3745

    PKA Others
    H1-7 (histone H1 phosphorylation site), PKA Substrate, a synthetic polypeptide, can be used as PKA substrate .
    H1-7 (histone H1 phosphorylation site), PKA Substrate
  • HY-123520

    G Protein-coupled Receptor Kinase (GRK) PKA Cancer
    GSK299115A is a G Protein-coupled Receptor Kinase (GRK) and PKA inhibitor .
    GSK299115A
  • HY-100530B

    PKA Phosphodiesterase (PDE) Neurological Disease Metabolic Disease
    Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS binds the PDE10 GAF domain with an EC50 of 40 μM .
    Sp-cAMPS
  • HY-100530C

    PKA Phosphodiesterase (PDE) Neurological Disease Metabolic Disease
    Sp-cAMPS sodium salt, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS sodium salt is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS sodium salt binds the PDE10 GAF domain with an EC50 of 40 μM .
    Sp-cAMPS sodium salt
  • HY-110005

    PKA Phosphodiesterase (PDE) Neurological Disease Metabolic Disease
    Sp-cAMPS triethylamine, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS triethylamine is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS triethylamine binds the PDE10 GAF domain with an EC50 of 40 μM .
    Sp-cAMPS triethylamine
  • HY-P3920

    PKA Cancer
    Cys-Kemptide is a cysteine-terminated substrate peptide that can used to measure protein kinase A (PKA) activity .
    Cys-Kemptide
  • HY-B0764B

    Dibutyryl cAMP; DBcAMP

    PKA Neurological Disease
    Bucladesine (DBcAMP) is a membrane permeable selective activator that activates cyclic adenosine phosphate dependent protein kinase A (PKA). The main regulatory mechanism of Bucladesine involves the cAMP/PKA signaling pathway. When Bucladesine activates PKA, it can promote a variety of cellular processes, including neurodevelopment, growth and plasticity. In particular, the cAMP/PKA signaling pathway plays a key role in the expression of long-term enhancement (LTP) and long-term inhibition (LTD), as well as in the formation of long-term memory in the hippocampus. Bucladesine can be used to study memory formation and neuroplasticity .
    Bucladesine
  • HY-134298

    8-(4-Chlorophenylthio)-N6-phenyl-cAMP

    PKA Others
    8-CPT-6-Phe-cAMP is an analogue of signal molecule cAMP and a potent protein kinase A (PKA) activator .
    8-CPT-6-Phe-cAMP
  • HY-134332

    8-(4-Chlorophenylthio)-5'-AMP

    PKA PKG Others
    8-pCPT-5'-AMP is an analogue of 5'-AMP and a lipophilic activator of PKA, PKG and Epac (exchange protein activated by cAMP) .
    8-pCPT-5'-AMP
  • HY-N1420

    L-Rhamnose

    Endogenous Metabolite MMP Interleukin Related PKA Cancer
    Rhamnose (L-Rhamnose) is an orally active deoxysugar that is widely found in plants and bacteria. Rhamnose can inhibit levels of pro-inflammatory interleukin and matrix metalloproteinases (MMPs) in skin aging models, showing anti-aging effects. Rhamnose can promote the phosphorylation levels of PKA substrates and HSL in SVF-derived adipocytes, stimulating PKA signaling. Rhamnose can act against obesity in mice by stimulating fat dopamine receptors and inducing thermogenesis. Rhamnose is also used in cancer research .
    Rhamnose
  • HY-120994B

    PKA Neurological Disease Inflammation/Immunology
    Sp-8-CPT-cAMPS, a cAMP analog, is a potent and selective activator of the cAMP-dependent protein kinas A (PKA I and PKA II). Sp-8-CPT-cAMPS selects site A of RI compares to site A of RII by 153-fold and site B of RII compares to site B of RI by 59-fold .
    Sp-8-CPT-cAMPS
  • HY-131777

    Others Others
    2-Cl-cAMP is an analog of cAMP and a potent stimulator of cAMP-dependent protein kinases such as PKA type I and II. 2-Cl-cAMP can be used as starting material for cyclic nucleotides .
    2-Cl-cAMP
  • HY-108047

    Phosphodiesterase (PDE) Metabolic Disease Inflammation/Immunology
    MK-0873 is a selective phosphodiesterase-4 (PDE4) inhibitor. MK-0873 increases intracellular levels of cyclic adenosine phosphate (cAMP) by inhibiting the activity of the PDE4 enzyme and subsequently activates protein kinase A (PKA). Activated PKA inhibits the activity of inflammatory cells and leads to direct relaxation of airway smooth muscle. MK-0873 can be used in studies of chronic obstructive pulmonary disease (COPD) .
    MK-0873
  • HY-142066

    PKA ERK iGluR Neurological Disease
    4′-Demethylnobiletin is a bioactive metabolite that activates the PKA/ERK/CREB signaling pathway, enhances CRE-mediated transcription in hippocampal neurons, and reverses memory impairment associated with NMDA receptor antagonism by stimulating ERK signaling .
    4′-Demethylnobiletin
  • HY-137530

    8-Methylamino-cAMP

    PKA Others
    8-MA-cAMP (8-Methylamino-cAMP) is a cyclic AMP analog that acts as a site-selective PKA agonist with similar affinity for the B site of type I and type II protein kinase A. 8-MA-cAMP is used in conjunction with priming analogs that show site A preference, such as 8-piperidinyl cAMP, to achieve selective stimulation of type I .
    8-MA-cAMP
  • HY-112412

    PDGF Receptor Tyrosine Kinase Inhibitor III

    PDGFR Neurological Disease
    PDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III), a multikinase inhibitor, inhibits PDGFR, EGFR, FGFR, PKA, and PKC, respectively. PDGFR Tyrosine Kinase Inhibitor III can be used for the research of amyotrophic lateral sclerosis .
    PDGFR Tyrosine Kinase Inhibitor III
  • HY-134263

    PKA Ras Cardiovascular Disease
    8-Br-cAMP-AM is a cyclic adenosine monophosphate (cAMP) analog that activates two major signal transduction pathways in the heart by mimicking the effects of cAMP: protein kinase A (PKA) and guanosine nucleotide exchange factor (Epac), which is directly activated by cAMP. 8-Br-cAMP-AM can be used to study cardiac ischemia and reperfusion injury .
    8-Br-cAMP-AM
  • HY-120994

    PKA Neurological Disease Inflammation/Immunology
    Rp-8-CPT-cAMPS sodium, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS sodium preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI .
    Rp-8-CPT-cAMPS sodium
  • HY-120994A

    PKA Neurological Disease Inflammation/Immunology
    Rp-8-CPT-cAMPS, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI .
    Rp-8-CPT-cAMPS
  • HY-134308

    Fluorescent Dye Others
    8-NBD-cAMP sodium is a fluorescently labeled cyclic adenosine phosphate (cAMP) analogue. 8-NBD-cAMP sodium retains a similar biological activity to cAMP, regulating their activity by binding to specific proteins such as EPACs or PKA. 8-NBD-cAMP sodium can be used in fluorescent competitive binding experiments to evaluate the binding affinity of newly synthesized EPAC1 agonists to EPAC1 proteins .
    8-NBD-cAMP sodium
  • HY-137381

    N6-Benzoyl-cAMP

    Potassium Channel Others
    6-Bnz-cAMP (N6-Benzoyl-cAMP), a derivative of cyclic adenosine monophosphate (cAMP), is a potent inhibitor of the bTREK-1 potassium channel. 6-Bnz-cAMP can strongly inhibit the bTREK-1 potassium channel through a protein kinase A (PKA) independent mechanism. 6-Bnz-cAMP can be used to explore potential signal transduction proteins in the cAMP signaling pathway .
    6-Bnz-cAMP
  • HY-143898

    Pim Cancer
    PIM1-IN-4 (Compound 8) is a potent inhibitor of PIM1. PIM1-IN-4 reveals strong inhibition of five other enzymes, i.e., SGK-1, PKA, CaMK-1, GSK3β, and MSK1. PIM1-IN-4 has the potential for the research of cancer diseases .
    PIM1-IN-4
  • HY-134302

    8-Hexylamino-cAMP

    PKA Others
    8-HA-cAMP is a membrane-permeable cAMP analogue and an activator of cAMP-dependent protein kinase and PKA I. 8-HA-cAMP exerts metabolic stability towards mammalian cyclic nucleotide-responsive phosphodiesterases .
    8-HA-cAMP
  • HY-W394717

    PGN 1531

    Prostaglandin Receptor PKA Others
    BGC-20-1531 (PGN 1531), a benzenesulfonamide derivative, is a selective EP4 antagonist. BGC-20-1531 binds to PGE2 enhancing the ATPase activity, which are coupled to Gs proteins and thus activate adenylate cyclase generating cAMP and activating PKA. BGC-20-1531 is promising for research of liver disorders .
    BGC-20-1531
  • HY-123468

    Cyclic GMP-AMP Synthase PKA ERK Calcium Channel Cardiovascular Disease Metabolic Disease
    HA-1004 is a selective inhibitor of PKA, which can inhibit lipolysis and induce vascular relaxation. HA-1004 is also a dual inhibitor of cyclic GMP-dependent protein kinase and cyclic AMP-dependent protein, and is involved in smooth muscle, second messenger, cyclic AMP and cyclic GMP regulation mechanisms. HA-1004 is an antagonist for calcium, that can be used as a vasodilator to inhibit the contraction of rabbit aortic strips, or to antagonize ERK and tyrosine hydroxylase (TH) phosphorylation in morphine abstinence rat models .
    HA-1004
  • HY-123468A

    Cyclic GMP-AMP Synthase PKA ERK Calcium Channel Cardiovascular Disease Metabolic Disease
    HA-1004 dihydrochloride is a selective inhibitor of PKA, which can inhibit lipolysis and induce vascular relaxation. HA-1004 dihydrochloride is also a dual inhibitor of cyclic GMP-dependent protein kinase and cyclic AMP-dependent protein, and is involved in smooth muscle, second messenger, cyclic AMP and cyclic GMP regulation mechanisms. HA-1004 dihydrochloride is an antagonist for calcium, that can be used as a vasodilator to inhibit the contraction of rabbit aortic strips, or to antagonize ERK and tyrosine hydroxylase (TH) phosphorylation in morphine abstinence rat models .
    HA-1004 di(hydrochloride)
  • HY-N6791
    KT5823
    5+ Cited Publications

    PKA PKC Bacterial Apoptosis Antibiotic Infection Inflammation/Immunology
    KT5823, a selective the cGMP-dependent protein kinase (PKG) inhibitor with an Ki value of 0.23 μM, it also inhibits PKA and PKC with Ki values of 10 μM and 4 μM, respectively. KT5823 is a Staurosporine-related protein kinase inhibitor, increases thyroid-stimulating hormone-induced (Na +/I - symporter) NIS expression, and iodide uptake in thyroid cells. KT5823 arrests cells after the G0/G1 boundary and causes increases in the levels of apoptotic DNA fragmentation .
    KT5823
  • HY-142654

    Liposome Others
    ATX-002 is an ionizable cationic lipid for RNA drug delivery. The calculated pKa (c-pKa) and measured pKa values for ATX-002 are 8.68 and 6.03, respectively .
    ATX-002
  • HY-P2261

    PKA Infection
    STAD 2 is a potent and selective disruptor of PKA-RII, with a Kd of 6.2 nM. STAD 2 disrupts interactions between PKA and AKAP in an isoform-selective manner. STAD 2 displays antimalarial activity through a PKA-independent mechanism .
    STAD 2
  • HY-158796

    Liposome Others
    L202 is an ionizable cationic lipid (pKa=6.04) that can be used for the study of mRNA and lipid nanoparticles .
    L202
  • HY-P10319

    PKA Cardiovascular Disease Cancer
    RI-STAD-2 is a high-affinity interfering peptide that regulates the subunit RI of protein kinase A (PKA). RI-STAD-2 interferes with the binding of AKAPs and PKA-RI by simulating the interaction between AKAPs' α-helix domain and PKA-RI's dimerization/anchoration (D/D) domain, thereby affecting PKA activity and intracellular localization. RI-STAD-2 can be used to study the role of AKAPs interaction with PKA-RI in pathological processes such as cardiovascular disease and cancer .
    RI-STAD-2
  • HY-46759

    Liposome Infection
    Genevant CL1 is an ionizable lipid (lipid 10, pKa=6.3), and it can be used for mRNA lipid nanoparticle (LNP) vaccine delivery [1][2].
    Genevant CL1
  • HY-46759A

    Liposome Infection
    Genevant CL1 monohydrochloride is an ionizable lipid (lipid 10, pKa=6.3), and it can be used for mRNA lipid nanoparticle (LNP) vaccine delivery .
    Genevant CL1 monohydrochloride
  • HY-156630
    Ionizable lipid-1
    1 Publications Verification

    Liposome Others
    Ionizable lipid-1 (compound II-10) is an ionizable lipid (pKa=6.16) that can be used to prepare lipid nanoparticles (LNP) with bilayer structure .
    Ionizable lipid-1
  • HY-156630A

    Liposome Others
    Ionizable lipid-1 (compound II-10) is an ionizable lipid (pKa=6.16) that can be used to prepare lipid nanoparticles (LNP) with bilayer structure .
    Ionizable lipid-1 hydrochloride
  • HY-23430

    Biochemical Assay Reagents Others
    TES is a buffering agent (pKa=7.550 at 25°C). TES is one of the Good's buffers, the buffer capacity ranging pH 6.8-8.2 .
    TES
  • HY-23430A

    Biochemical Assay Reagents Others
    TES sodium is a buffering agent (pKa=7.550 at 25°C). TES sodium is one of the Good's buffers, the buffer capacity ranging pH 6.8-8.2 .
    TES sodium
  • HY-126376

    PKC PKA Others
    Iso-​H7 dihydrochloride is an inhibitor of protein kinase with IC50 values of 22 and 34 μM to PKC and PKA respectively. Iso-H7 dihydrochloride has negative control of PKA on satellite cell myogenesis .
    Iso-​H7 dihydrochloride
  • HY-23430S

    Isotope-Labeled Compounds Others
    TES-d15 is the deuterium labeled TES[1]. TES is a buffering agent (pKa=7.550 at 25°C). TES is one of the Good's buffers, the buffer capacity ranging pH 6.8-8.2[2][3].
    TES-d15
  • HY-P3785

    PKA Neurological Disease
    PKI(5-22)amide is the active inhibitory fragment of the inhibitor of the cyclic AMP-dependent protein kinase (PKA). PKI(5-22)amide inhibits PKA activation, but fails to attenuate homologous desensitization of CRF1 receptors .
    PKI(5-22)amide
  • HY-N9725

    16ξ-Hydroxycleroda-3,13-dien-15,16-olide

    Dipeptidyl Peptidase Metabolic Disease
    16-Hydroxycleroda-3,13-dien-15,16-olide (16ξ-Hydroxycleroda-3,13-dien-15,16-olide; HCD), a clerodane diterpene, is a potent serine protease dipeptidyl peptidase 4 (DPP-4) inhibitor. 16-Hydroxycleroda-3,13-dien-15,16-olide down-regulates LPS-induced ERK phosphorylation in myocyte but blocks GLP-1 induced PKA expression. 16-Hydroxycleroda-3,13-dien-15,16-olide exhibits hypolipidemic, hepatoprotective, hypoglycemic efficacy .
    16-Hydroxycleroda-3,13-dien-15,16-olide
  • HY-P0248

    PKA Metabolic Disease
    Kemptide is a synthetic heptapeptide that acts as a specific substrate for cAMP-dependent protein kinase (PKA).
    Kemptide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: